A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...
TV sets at the headquarters of the Department of Housing and Urban Development played the seemingly AI-generated video on ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Schrödinger today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E ...
Petra Cares is proud to announce the 2nd Annual Petra Cares Gala, a fundraising event dedicated to empowering young adults transitioning out of foster care and homeless, at-risk youth. The gala will ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
MarketBeat on MSN3d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback